Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (271-280 of 314) with videos related to

Pageof 32
Sort By:
The New England Journal of Medicine|November 16, 2017
Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Thierry Gorlia, Martin Bendszus, et al.
Neuro-Oncology|April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteriaLakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
The Journal of Clinical Investigation|February 16, 2026
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma modelShashwat Tripathi, Hinda Najem, Lisa Hurley, et al.
The Journal of Clinical Investigation|August 13, 2024
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytomaShashwat Tripathi, Hinda Najem, Corey Dussold, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
JAMA Oncology|February 3, 2018
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical TrialMartin J B Taphoorn, Linda Dirven, Andrew A Kanner, et al.
The Lancet. Oncology|October 1, 2016
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyJaap C Reijneveld, Martin J B Taphoorn, Corneel Coens, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Pageof 32

Showing results (271-280 of 314) with videos related to

Sort By:
Pageof 32
The New England Journal of Medicine|November 16, 2017
Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Thierry Gorlia, Martin Bendszus, et al.
Neuro-Oncology|April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteriaLakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
The Journal of Clinical Investigation|February 16, 2026
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma modelShashwat Tripathi, Hinda Najem, Lisa Hurley, et al.
The Journal of Clinical Investigation|August 13, 2024
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytomaShashwat Tripathi, Hinda Najem, Corey Dussold, et al.
The Lancet. Oncology|December 7, 2017
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' replyMichael Weller, Nicholas Butowski, David D Tran, et al.
The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.
JAMA Oncology|February 3, 2018
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical TrialMartin J B Taphoorn, Linda Dirven, Andrew A Kanner, et al.
The Lancet. Oncology|October 1, 2016
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyJaap C Reijneveld, Martin J B Taphoorn, Corneel Coens, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Pageof 32